Lead Causing Early Menopause

by | Mar 5, 2014

 
Women who accumulate the highest lead levels are more likely to experience early menopause, according to new research epublished January 3, 2014.
In a study of 401 women from the Boston area, those with the highest levels of lead in their shinbone were 5 times more likely than women with the lowest levels to experience menopause before the age of 45, according to the report from the Harvard School of Public Health.
It is the first study to link long-term, low-level lead exposure to early menopause, a condition that raises the risk of heart disease and other health effects.
“The success in reducing external lead exposures in the US may mean that women entering menopause today are at less risk of lead-associated earlier age at menopause than we observed,” the authors wrote in the study published online at Environmental Health Perspectives last week.
Nevertheless, they added that “the possibility remains that further reductions in lead levels could still improve the health of women as they age.”
The researchers compared the age of menopause with lead levels in the blood, shinbone (tibia) and kneecap (patella) of women enrolled in the Nurses’ Health Study, a group tracked by health researchers since 1976. Breaking the women into three groups based on the levels of lead in their tibias, researchers found that the average age of menopause for women with the highest levels was 1.21 years younger than those with the lowest levels.
There was no association between blood or patella bone lead levels and age of menopause onset.
It is not clear why only tibia levels were associated with earlier menopause. It could be that lead doesn’t stay in blood too long and bone lead levels are indicative of long-term exposure, the study authors said.
The study is limited in that the bone lead measures were made mostly after menopause for most women. In addition, only 23 of the women experienced menopause before the age of 45, which is a small sample. The average age was 51.
Results: Higher tibia lead level was associated with younger age at menopause. In adjusted analyses, the average age of menopause for women in the highest tertile of tibia lead was 1.21 years younger (95% CI: –2.08, –0.35) than for women in the lowest tertile (p-trend = 0.006). Although the number of cases was small (n = 23), the odds ratio for early menopause (< 45 years of age) was 5.30 (95% CI: 1.42, 19.78) for women in the highest tertile of tibia lead compared with those in the lowest tertile (p-trend = 0.006).

Source: Eum, KD, MG Weisskopf, LH Nie, H Hu, SA Korrick. 2014. Cumulative lead exposure and age at menopause in the Nurses’ Health Study cohort. Environmental Health Perspectives. DOI:10.1289/ehp.1206399 Synopsis by: Brian Bienkowski

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

11 + 14 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });